Sildenafil treatment attenuates ventricular remodeling in an experimental model of aortic regurgitation

[1]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[2]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[3]  D. Kass,et al.  Hypertrophy Signaling Pathways in Experimental Chronic Aortic Regurgitation , 2013, Journal of Cardiovascular Translational Research.

[4]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[5]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.

[6]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease. , 2007, European heart journal.

[7]  Sang-Eun Lee,et al.  Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity , 2012, Circulation.

[8]  R. Stewart,et al.  Medical treatment of asymptomatic chronic aortic regurgitation , 2011, Expert review of cardiovascular therapy.

[9]  J. McMullen,et al.  Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. , 2010, Pharmacology & therapeutics.

[10]  V. Regitz-Zagrosek,et al.  Differential Cardiac Remodeling in Preload Versus Afterload , 2010, Circulation.

[11]  R. Bonow,et al.  Valvular heart disease: diagnosis and management. , 2010, Mayo Clinic proceedings.

[12]  D. Kass,et al.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. , 2009, Pharmacology & therapeutics.

[13]  K. Sipido,et al.  Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice , 2009, Circulation.

[14]  R. Arena,et al.  Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.

[15]  G. Lewis,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[16]  Helmut Baumgartner,et al.  Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology , 2007 .

[17]  Marc A Pfeffer,et al.  Controversies in ventricular remodelling , 2006, The Lancet.

[18]  M. Beckerle,et al.  Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. , 2005, The Journal of clinical investigation.

[19]  A. Evangelista,et al.  Long-term vasodilator therapy in patients with severe aortic regurgitation. , 2005, The New England journal of medicine.

[20]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[21]  D. Lachance,et al.  Effectiveness of &bgr;-Blockade in Experimental Chronic Aortic Regurgitation , 2004 .

[22]  M. Borst,et al.  Regulation of protein kinase C isozymes in volume overload cardiac hypertrophy , 2004, Molecular and Cellular Biochemistry.

[23]  D. Kass,et al.  Modulation of In Vivo Cardiac Function by Myocyte-Specific Nitric Oxide Synthase-3 , 2004, Circulation research.

[24]  D. Lachance,et al.  Effectiveness of beta-blockade in experimental chronic aortic regurgitation. , 2004, Circulation.

[25]  A. Rosenzweig,et al.  Akt and PI 3-Kinase Signaling in Cardiomyocyte Hypertrophy and Survival , 2003, Cell cycle.

[26]  J. Couet,et al.  Left ventricular response to sustained volume overload from chronic aortic valve regurgitation in rats. , 2003, Journal of cardiac failure.

[27]  J. Couet,et al.  Experimental aortic regurgitation in rats under echocardiographic guidance. , 2002, The Journal of heart valve disease.

[28]  F. Ståhlberg,et al.  Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation. , 2000, American heart journal.

[29]  M. Enriquez-Sarano,et al.  Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. , 1999, Circulation.

[30]  R. Bonow,et al.  Survival and functional results after valve replacement for aortic regurgitation from 1976 to 1983: impact of preoperative left ventricular function. , 1985, Circulation.

[31]  Michael V. Green,et al.  Reversal of left ventricular dysfunction after aortic valve replacement for chronic aortic regurgitation: influence of duration of preoperative left ventricular dysfunction. , 1984, Circulation.

[32]  B MAYNE,et al.  On aortic regurgitation , 1953, Irish journal of medical science.